A Phase 1 Randomized Double-blind Placebo-controlled Single Ascending Dose Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a

Brief description of study

This research study is being conducted to learn more about the effects of a new therapy, AMG 890. In animals, AMG 890 lowered the levels of Lp(a) in the blood, and it is being investigated for the treatment of cardiovascular disease. The purpose of this study is to obtain initial information on the safety and tolerability, pharmacokinetics, and pharmacodynamics of a single dose of AMG 890 in participants with elevated levels of Lp(a) in the blood. AMG 890 is being developed by Amgen Inc., a for-profit biopharmaceutical company. AMG 890 is experimental, which means it is not approved by the US Food and Drug Administration (FDA).

Clinical Study Identifier: s19-00369
ClinicalTrials.gov Identifier: NCT03626662
Principal Investigator: Howard Weintraub.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.